Vancomycin-resistant enterococcal infections.

Enterococci are best known as antibiotic-resistant opportunistic pathogens that are commonly recovered from patients who have received multiple courses of antibiotics and have been hospitalized for prolonged periods.1–6 These organisms were well established as a cause of endocarditis and urinary tract infections by the early 1900s,3 and members of the species Enterococcus faecalis were known to be a common cause of nosocomial infections by the early 1980s.3,7–9 The emergence of enterococci with resistance to vancomycin, seen predominantly in the species E. faecium, has been followed by an increase in the frequency with which this species is recovered. . . .

[1]  R A Weinstein,et al.  A Comparison of the Effect of Universal Use of Gloves and Gowns with That of Glove Use Alone on Acquisition of Vancomycin-Resistant Enterococci in a Medical Intensive Care Unit , 1996, Annals of Internal Medicine.

[2]  R. Eng,et al.  Vancomycin-resistant Enterococcus faecium in a Veterans Affairs Medical Center: association with antibiotic usage. , 1998, American journal of infection control.

[3]  M. Evans,et al.  Vancomycin Use in a University Medical Center: Comparison With Hospital Infection Control Practices Advisory Committee Guidelines , 1996, Infection Control & Hospital Epidemiology.

[4]  J. Lemeland,et al.  Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. , 1995, The Journal of infectious diseases.

[5]  S. Nachman,et al.  Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. , 1995, Microbial Drug Resistance.

[6]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[7]  P. Courvalin,et al.  VanD-type glycopeptide-resistant Enterococcus faecium BM4339 , 1997, Antimicrobial agents and chemotherapy.

[8]  F. Tenover,et al.  Detection of vancomycin-resistant enterococci in fecal samples by PCR , 1997, Journal of clinical microbiology.

[9]  F. Moreno,et al.  Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Bisno,et al.  Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. , 1995, JAMA.

[11]  R. Leclercq,et al.  Resistance to glycopeptides in enterococci. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Armstrong,et al.  Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. , 1996, The Pediatric infectious disease journal.

[13]  B. Murray,et al.  Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci , 1994, Antimicrobial Agents and Chemotherapy.

[14]  D. Sexton,et al.  Resistant Enterococci: A Prospective, Study of Prevalence, Incidence, and Factors Associated With Colonization in a University Hospital , 1996, Infection Control & Hospital Epidemiology.

[15]  W. Bilker,et al.  The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  S. Ricke,et al.  Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States , 1996, Antimicrobial agents and chemotherapy.

[17]  G. Eliopoulos,et al.  In vitro activities in new oxazolidinone antimicrobial agents against enterococci , 1996, Antimicrobial agents and chemotherapy.

[18]  C. Walsh,et al.  Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. , 1991, Biochemistry.

[19]  D. Thompson,et al.  Historical Yearly Usage of Vancomycin , 1998, Antimicrobial Agents and Chemotherapy.

[20]  F. Allerberger,et al.  In-vitro activity of fosfomycin against vancomycin-resistant enterococci. , 1999, The Journal of antimicrobial chemotherapy.

[21]  J. Lemeland,et al.  In vitro interactions between different beta-lactam antibiotics and fosfomycin against bloodstream isolates of enterococci , 1995, Antimicrobial agents and chemotherapy.

[22]  J. Warren,et al.  Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Pegues,et al.  Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital , 1997, Journal of clinical microbiology.

[24]  A. Tomasz,et al.  Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York City hospital. , 1996, Microbial drug resistance.

[25]  M. Arthur,et al.  Requirement of the VanY and VanX D,D‐peptidases for glycopeptide resistance in enterococci , 1998, Molecular microbiology.

[26]  G. Wormser,et al.  Bloodstream infections with vancomycin-resistant enterococci. , 1996, Archives of internal medicine.

[27]  L. Bopp,et al.  Genetic Analysis of Multiple Vancomycin-ResistantEnterococcus Isolates Obtained Serially from Two Long-Term-Care Patients , 1998, Journal of Clinical Microbiology.

[28]  M. Arthur,et al.  The VanS sensor negatively controls VanR-mediated transcriptional activation of glycopeptide resistance genes of Tn1546 and related elements in the absence of induction , 1997, Journal of bacteriology.

[29]  B. Murray The life and times of the Enterococcus , 1990, Clinical Microbiology Reviews.

[30]  B. Farr,et al.  Disinfection of Hospital Rooms Contaminated With Vancomycin-Resistant Entemcocms faecium , 1998, Infection Control & Hospital Epidemiology.

[31]  G. Wormser,et al.  A semiquantitative analysis of the fecal flora of patients with vancomycin-resistant enterococci: colonized patients pose an infection control risk. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  T. L. Hodges,et al.  Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens , 1992, Antimicrobial Agents and Chemotherapy.

[33]  P. Vandamme,et al.  Isolation of glycopeptide resistant Streptococcus gallolyticus strains with vanA, vanB, and both vanA and vanB genotypes from faecal samples of veal calves in The Netherlands. , 1998, The Journal of antimicrobial chemotherapy.

[34]  M. Zervos,et al.  A New High-Level Gentamicin Resistance Gene,aph(2")-Id, in Enterococcus spp , 1998, Antimicrobial Agents and Chemotherapy.

[35]  P. Murray,et al.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis , 1989, Antimicrobial Agents and Chemotherapy.

[36]  A. Simor,et al.  Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  G. Satta,et al.  Intrinsic penicillin resistance in enterococci. , 1996, Microbial drug resistance.

[38]  B. Murray,et al.  Beta-lactamase-producing enterococci , 1992, Antimicrobial Agents and Chemotherapy.

[39]  S. Handwerger,et al.  Mobilization of vancomycin resistance by transposon-mediated fusion of a VanA plasmid with an Enterococcus faecium sex pheromone-response plasmid. , 1996, Gene.

[40]  W. Lynn,et al.  Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin , 1994, The Lancet.

[41]  R. Weinstein,et al.  Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  W. C. Miller,et al.  Relapsing Native‐Valve Enterococcal Endocarditis: A Unique Cure with Oral Ciprofloxacin Combination Drug Therapy , 1991, Journal of clinical pharmacology.

[43]  J. Duval,et al.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. , 1988, The New England journal of medicine.

[44]  V. Yu,et al.  Treatment Options for Chronic Prostatitis due to Vancomycin-Resistant Enterococcus faecium , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[45]  L. Peterson,et al.  Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. , 1995, Microbial drug resistance.

[46]  J. Boyce,et al.  Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance , 1994, Journal of clinical microbiology.

[47]  B. Cookson,et al.  Diversity of VanA Glycopeptide Resistance Elements in Enterococci from Humans and Nonhuman Sources , 1998, Antimicrobial Agents and Chemotherapy.

[48]  N. Mobarakai,et al.  Ampicillin plus ciprofloxacin therapy of experimental endocarditis caused by multidrug-resistant Enterococcus faecium. , 1995, The Journal of antimicrobial chemotherapy.

[49]  J. S. Daly,et al.  High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  R. Wenzel,et al.  Nosocomial urinary tract infections due to enterococcus. Ten years' experience at a university hospital. , 1986, Archives of internal medicine.

[51]  R. Gaynes,et al.  A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. , 1992 .

[52]  G. Woods,et al.  Hospital-acquired Infection with Vancomycin-resistant Enterococcus faecium Transmitted by Electronic Thermometers , 1992, Annals of Internal Medicine.

[53]  R. Wenzel,et al.  Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. , 1989, American journal of infection control.

[54]  G. Eliopoulos,et al.  Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci , 1992, Antimicrobial Agents and Chemotherapy.

[55]  W. Witte,et al.  Glycopeptide-resistant Enterococcus faecium outside Hospitals: a commentary. , 1995, Microbial drug resistance.

[56]  G. Trenholme,et al.  In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. , 1993, The Journal of infectious diseases.

[57]  L. Adinolfi,et al.  Successful Treatment with Ampicillin and Fluoroquinolones of Human Endocarditis due to High-Level Gentamicin-Resistant Enterococci , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[58]  N. Rolando,et al.  Serious infections caused by multiply-resistant Enterococcus faecium. , 1995, Microbial drug resistance.

[59]  G. Talbot,et al.  The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium , 1999 .

[60]  B. Murray,et al.  Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis , 1994, Antimicrobial Agents and Chemotherapy.

[61]  F. Cockerill,et al.  DNA sequence resembling vanA and vanB in the vancomycin-resistant biopesticide Bacillus popilliae. , 1998, The Journal of infectious diseases.

[62]  R N Jones,et al.  Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. , 1995, Diagnostic microbiology and infectious disease.

[63]  P. Courvalin,et al.  Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. , 1994, FEMS microbiology letters.

[64]  L. Riley,et al.  Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  R. Gaynes,et al.  Major trends in the microbial etiology of nosocomial infection. , 1991, The American journal of medicine.

[66]  B. Fantin,et al.  Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis , 1997, Antimicrobial agents and chemotherapy.

[67]  G. Eliopoulos,et al.  Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis , 1990, Antimicrobial Agents and Chemotherapy.

[68]  P. Courvalin,et al.  Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens , 1994, Antimicrobial Agents and Chemotherapy.

[69]  A. Goldstone,et al.  The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. , 1999, The Journal of antimicrobial chemotherapy.

[70]  J. Mainardi,et al.  Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. , 1998, The Journal of infectious diseases.

[71]  P. Sisson,et al.  Therapeutic beds: the Trojan horses of the 1990s? , 1994, The Lancet.

[72]  E. Dejesus,et al.  Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model , 1996, Antimicrobial agents and chemotherapy.

[73]  B. Murray,et al.  beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. , 1987, The Journal of infectious diseases.

[74]  F. Aarestrup,et al.  Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster , 1996, Antimicrobial agents and chemotherapy.

[75]  L. Peterson,et al.  Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  B. Murray,et al.  High-level resistance to gentamicin in clinical isolates of enterococci. , 1983, The Journal of infectious diseases.

[77]  N. Schupf,et al.  Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. , 1998 .

[78]  N. Woodford,et al.  VANCOMYCIN-RESISTANT ENTEROCOCCI , 1988, The Lancet.

[79]  M. Rupp,et al.  Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period , 1997, Antimicrobial agents and chemotherapy.

[80]  F. Tenover,et al.  Characterization of glycopeptide-resistant enterococci from U.S. hospitals , 1993, Antimicrobial Agents and Chemotherapy.

[81]  G. Wormser,et al.  Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. , 1995, The Journal of infectious diseases.

[82]  S. Handwerger,et al.  Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. , 1996, Microbial drug resistance.

[83]  J. Fung,et al.  Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[84]  C Brennen,et al.  Vancomycin‐Resistant Enterococcus faecium in a Long‐Term Care Facility , 1998, Journal of the American Geriatrics Society.

[85]  D. Dunn,et al.  Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[86]  M. Arthur,et al.  Mechanisms of glycopeptide resistance in enterococci. , 1996, The Journal of infection.

[87]  R. Leclercq,et al.  Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. , 1996, The Journal of infectious diseases.

[88]  M. Levison,et al.  Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium , 1993, Antimicrobial Agents and Chemotherapy.

[89]  J. Elion,et al.  Evidence for the genetic unrelatedness of nosocomial vancomycin-resistant Enterococcus faecium strains in a pediatric hospital , 1991, Journal of clinical microbiology.

[90]  W. Scheld,et al.  Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. , 1997, Archives of internal medicine.

[91]  J. Morris,et al.  Recurrent vancomycin-resistant Enterococcus faecium bacteremia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[92]  M. Cohen,et al.  In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci , 1995, Antimicrobial agents and chemotherapy.

[93]  D. Maki,et al.  Enterococcal Bacteremia: Clinical Features, the Risk of Endocarditis, and Management , 1988, Medicine.

[94]  P. Courvalin,et al.  VanE, a New Type of Acquired Glycopeptide Resistance in Enterococcus faecalis BM4405 , 1999, Antimicrobial Agents and Chemotherapy.

[95]  R. Bégué,et al.  Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. , 1999, The Pediatric infectious disease journal.

[96]  R. Weinstein,et al.  The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. , 1999, The Journal of infectious diseases.

[97]  C. Stratton,et al.  Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. , 1996, The Journal of infectious diseases.

[98]  P. Brennan,et al.  Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[99]  R. Moellering,et al.  The enterococcus: "putting the bug in our ears". , 1987, Annals of internal medicine.

[100]  T. Rakowski,et al.  Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[101]  G. Eliopoulos,et al.  Vancomycin-resistant Enterococcus faecium in hospitalized children. , 1992 .

[102]  K. Singh,et al.  Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[103]  G. Papanicolaou,et al.  Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  R. Wenzel,et al.  Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  Ronald N. Jones,et al.  Molecular Analysis of Tn1546 inEnterococcus faecium Isolated from Animals and Humans , 1998, Journal of Clinical Microbiology.

[106]  W. Noble,et al.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. , 1992, FEMS microbiology letters.

[107]  A. C. McIntosh,et al.  Isolation of vancomycin-resistant enterococci from animal feed in USA , 1999, The Lancet.

[108]  J. Duval,et al.  Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145 , 1993, Antimicrobial Agents and Chemotherapy.

[109]  M. Millar,et al.  Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. , 1997, Journal of Antimicrobial Chemotherapy.

[110]  R. Wenzel,et al.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[111]  D. Goldmann,et al.  Reducing the spread of antimicrobial-resistant microorganisms. Control of vancomycin-resistant enterococci. , 1995, Pediatric clinics of North America.

[112]  J. Morris,et al.  Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin: Establishment of Endemicity in a University Medical Center , 1995, Annals of Internal Medicine.

[113]  J. Bates,et al.  Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. , 1994, The Journal of antimicrobial chemotherapy.

[114]  Natural history of colonization with vancomycin-resistant Enterococcus faecium. , 1995, Infection control and hospital epidemiology.

[115]  L. Jensen,et al.  Vancomycin-resistant enterococci in turkeys and farmers. , 1997, The New England journal of medicine.

[116]  J. Duval,et al.  Transferable vancomycin and teicoplanin resistance in Enterococcus faecium , 1989, Antimicrobial Agents and Chemotherapy.

[117]  P. Courvalin,et al.  Characterization of Tn1547, a composite transposon flanked by the IS16 and IS256-like elements, that confers vancomycin resistance in Enterococcus faecalis BM4281. , 1996, Gene.

[118]  J. Chia,et al.  Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[119]  D. Landman,et al.  Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[120]  B. Fantin,et al.  Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. , 1997, The Journal of infectious diseases.

[121]  G. Eliopoulos Aminoglycoside resistant enterococcal endocarditis. , 1993, Infectious disease clinics of North America.

[122]  L. Rice,et al.  Genetic Linkage and Cotransfer of a Novel,vanB-Containing Transposon (Tn5382) and a Low-Affinity Penicillin-Binding Protein 5 Gene in a Clinical Vancomycin-Resistant Enterococcus faecium Isolate , 1998, Journal of bacteriology.

[123]  P. Linden,et al.  Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. , 1997, The Journal of antimicrobial chemotherapy.

[124]  R. Eng,et al.  Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. , 1994, Diagnostic microbiology and infectious disease.

[125]  J. Duval,et al.  Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci , 1991, Antimicrobial Agents and Chemotherapy.

[126]  P. Berche,et al.  Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis , 1997, Antimicrobial agents and chemotherapy.

[127]  G. Eliopoulos,et al.  Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium , 1997, Antimicrobial agents and chemotherapy.

[128]  M. Zervos,et al.  Treatment of Vancomycin-Resistant Enterococcus faeciumwith RP 59500 (Quinupristin-Dalfopristin) Administered by Intermittent or Continuous Infusion, Alone or in Combination with Doxycycline, in an In Vitro Pharmacodynamic Infection Model with Simulated Endocardial Vegetations , 1998, Antimicrobial Agents and Chemotherapy.

[129]  G. Losonsky,et al.  Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[130]  G. Wormser,et al.  Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium , 1995, Antimicrobial agents and chemotherapy.

[131]  T. Schiano,et al.  Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. , 1998, Transplantation.

[132]  G. Eliopoulos,et al.  In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms , 1993, Antimicrobial Agents and Chemotherapy.

[133]  C. Flexner,et al.  Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[134]  A. Ambergen,et al.  The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. , 1998, Archives of internal medicine.

[135]  S. Migliaresi,et al.  Combination of co-trimoxazole and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin. , 1997, The Journal of antimicrobial chemotherapy.

[136]  J. Conly,et al.  Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[137]  F. Moreno,et al.  An old antibiotic for a new multiple-resistant Enterococcus faecium? , 1994, Diagnostic microbiology and infectious disease.

[138]  P. Courvalin,et al.  Genetics of glycopeptide resistance in enterococci. , 1996, Microbial drug resistance.

[139]  H. Claus,et al.  vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. , 1995, FEMS microbiology letters.

[140]  Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. , 1995, JAMA.

[141]  A. Rendo,et al.  Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci , 1993, Journal of clinical microbiology.